The benefits and costs of tamoxifen for breast cancer prevention

Australian and New Zealand Journal of Public Health

Volumn 27, Issue 1, 2003, Pages 34-40

  Eckermann, Simon D ^a   Martin, Andrew J ^a,b   Stockler, Martin R ^a,c   Simes, R John ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Roche Products Pty Ltd   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TAMOXIFEN;

ARTICLE; AUSTRALIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CATARACT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; GYNECOLOGIC DISEASE; HEALTH STATUS; HIGH RISK PATIENT; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL DECISION MAKING; META ANALYSIS; MONTE CARLO METHOD; OUTCOMES RESEARCH; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; VASOMOTOR DISORDER;

EID: 0037286615     PISSN: 13260200     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1467-842X.2003.tb00377.x     Document Type: Article

References (32)

1. Fisher B, Costantino JP, Wickerham L, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
2. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
3. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998;352:93-7.
4. Pritchard KI. Is tamoxifen effective in prevention of breast cancer? Lancet 1998;352:80-1.
5. Day R, Ganz P, Costanino J, Cronin W, Wickerman D, Fisher B. Health related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Clin Oncol 1999;17:2659-69.
6. Kenny P, Viney R, Gerard K, Hall J, King M, Shanahan M. Managing breast cancer: What does economics have to offer? Health Economics Review [newsletter of CHERE]. Sydney: Centre for Health Economics Research and Evaluation, University of Sydney, 1999 December.
7. Smith T, Hillner B. Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women. J Clin Oncol 2000;18(2):284-6.
8. Noe LL, Becker RV III, Gradishar WJ, Gore M, Trotter JP. The cost-effectiveness of tamoxifen in the prevention of breast cancer. Am J Manag Care 1999;5Suppl 6:389-406.
9. Cuzick J. A brief review of the current breast cancer prevention trials and proposals for future trials. Eur J Cancer 2000;36:1298-302.
10. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making 1993;13:322-38.
11. Early Breast Cancer Trialist's Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998;352:930-42.
12. Early Breast Cancer Trialist's Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: An overview of the randomized trials. N Engl J Med 1995;333:1444-55.
13. Causes of Death. Canberra(ACT): Australian Bureau of Statistics, 1996. Catalogue No.: 3303.0.
14. Anderson CS, Jamrozik KD, Burvill PW, Chakera TM, Johnson GA, Stewart-Wynne EG. Ascertaining the true incidence of stroke: Experience from the Perth Community Stroke Study 1989-1990. Med J Aust 1993;158:80-4.
15. Lowel H, Dobson A, Keil U, et al. Coronary heart disease case fatality in four countries. A community study. The Acute Myocardial Infarction Register Teams of Auckland, Augsburg, Bremen, FINMONICA, Newcastle, and Perth. Circulation 1993;88:2524-31.
16. Supramaniam R, Smith DP, Coates MS, Armstrong BK. Survival from Cancer in NSW in 1980 to 1995. Sydney: New South Wales Cancer Council, 1999.
17. Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: Results of a multicenter registry. Circulation 1997;96:882-8.
18. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989;5:559-75.
19. Chie WC, Huang CS, Chen JH, Chang KJ. Utility assessment for different clinical phases of breast cancer in Taiwan. J Formosa Med Assoc 2000;99:677-83.
20. Hall J, Gerard K, Salkeld G, Richardson J. A cost utility analysis of mammography screening in Australia. Soc Sci Med 1992;34:993-1004.
21. Simes RJ. Application of statistical decision theory to treatment choices: Implications for the design and analysis of clinical trials. Stat Med 1986;5:411-20.
22. Gerard K, Dobson M, Hall J. Framing and labeling effects in health descriptions: Quality adjusted life years for treatment of breast cancer. J Clin Epidemiol 1993;46:77-84.
23. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: Including Submissions Involving Economic Analysis. Canberra(ACT): Department of Human Services and Health, 1995. p. 16.
24. Baker MS, Kessler LG, Urban N, Smucker RC. Estimating the treatment costs of breast and lung cancer. Med Care 1991;29:40-9.
25. Seymour J, Shiell A, Boyages J, et al. The Cost of Treatment for Early Stage Breast Cancer at Westmead Hospital. Sydney(NSW): Centre of Health Economics Research and Evaluation, University of Sydney, 2001. CHERE Discussion Series No.: 43.
26. Casemix Standards for New South Wales 1997-98. Sydney(NSW): NSW Department of Health, Structural and Funding Branch, 1998.
27. Pharmaceutical Benefits Scheme: Medicines in Australia. Canberra(ACT): Department of Health, Local Government and Community Services, 1997.
28. Medicare Benefits Schedule Book: Operating from 1 November. Canberra(ACT): Department of Health and Family Services, 1997.
29. Australian Institute of Health and Welfare. Health Expenditure Bulletin no. 15: Australia's Health Services Expenditure to 1997-98. Canberra(ACT): AIHW, 1999.
30. Briggs AH, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998;7:724-40.
31. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. Br Med J 1998;317:720-6.
32. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomized prevention trial. IBIS investigators and Jack Cuzick. Lancet 2002;360:817-24.